Ajanta Pharma reported a strong Q3 FY26 performance, with revenue from operations increasing by 20% to ₹1,375 crore. Profit after tax (PAT) also saw significant growth, rising by 18%. The company’s branded generics business, particularly in India, Asia, and Africa, continues to drive growth. US generics also contributed strongly with a 52% increase.
Financial Performance
Ajanta Pharma announced positive financial results for Q3 FY26:
- Revenue from operations: ₹1,375 crore (up 20% year-over-year)
- EBITDA: ₹382 crore (up 19%), with an EBITDA margin of 28%.
- Profit after tax (PAT): ₹274 crore (up 20%).
For the nine months ending December 31, 2025:
- Revenue from operations: ₹4,031 crore (up 16% year-over-year)
- EBITDA: ₹1,061 crore (up 10%), with an EBITDA margin of 26% (or 28% excluding forex losses).
- Profit after tax (PAT): ₹789 crore (up 14%).
Segment Performance
The company witnessed strong growth across key segments:
- Branded Generics (India): Revenue increased by 19% in Q3 FY26 and 15% in 9M FY26.
- Branded Generics (Asia): Experienced a slight decline of 9% in Q3 FY26 but saw a 1% increase in 9M FY26.
- Branded Generics (Africa): Revenue increased significantly by 33% in Q3 FY26 and 10% in 9M FY26.
- US Generics: Showed substantial growth with a 52% increase in Q3 FY26 and 46% in 9M FY26.
- Africa Institution: Declined by 6% in 9M FY26.
Strategic Focus
Ajanta Pharma continues to focus on:
- Launching new products across markets.
- Gaining market share in existing products.
- Expanding into new countries and therapies.
- Optimizing expenses.
- Digitalization across all functions.
Earnings Call Information
The company will host an earnings conference call on January 30, 2026. The details are:
- Time: 16:30 hrs IST.
- For dial-in details, visit the company website.
Source: BSE
